Dramatic Improvement in Suicidal Ideation After Brain Radiosurgery Capsulotomy

[Stereotactic Radiosurgical Capsulotomy Delivers Substantial Reduction in Suicidal Ideation for Treatment-Resistant Depression]

Patients with treatment-resistant depression and suicidal ideation demonstrated significant symptomatic improvement following radiosurgical treatment of a brain pathway implicated in mood and obsessive-compulsive behaviors, according to a small clinical trial.

Suicidal ideation resolved in 13 of 14 patients (93%), and depression symptom scores fell by more than half on average across 18 evaluable participants receiving radiosurgical capsulotomy. Eleven individuals experienced at least a 50% reduction in their individual Beck Depression Inventory (BDI) scores. All but two of the 20 enrolled subjects showed some level of improvement from baseline, with most benefits persisting for a year or longer.

No participant developed neurologic deficits, cognitive decline, personality changes, hemorrhage, or infections post‑treatment, stated Mohamed Khattab, M.D., University of South Florida, Tampa, during his presentation at the American Society for Radiation Oncology annual meeting in Boston.

“Thirteen of 14 patients presenting with suicidal ideation at enrollment—93% overall—achieved resolution of their emotional distress at final follow‑up. Potentially, this represents a life‑saving intervention. Even among those with the most severe illnesses and limited response to alternative therapies, observed depression gains began within three months and persisted thereafter. The magnitude of improvement given the severity and recalcitrance of the patients’ presentations is especially noteworthy.”

“The cohort consisted exclusively of individuals treated at a single institution with a modest sample size, and the trial lacked a sham‑control arm.” He continued, “Future work aims to conduct a sham‑controlled, randomized investigation incorporating functional imaging. Concurrently, ongoing dialogue with psychiatric colleagues is seeking optimal sequencing strategies when integrating these approaches.”

“The results warrant optimism yet should be interpreted against the backdrop of a limited, single‑center dataset,” advised ASTRO expert Markus Bredel, M.D., Ph.D., University of Miami Sylvester Comprehensive Cancer Center.

“For patients with the most entrenched forms of depression, conventional options frequently provide insufficient relief. This study offers value by evaluating a precisely targeted, incisionless modality for those who have exhausted multiple therapeutic avenues, while rigorously monitoring cognition and safety over time. While the drop in suicidal ideation appears pronounced, broader application depends on larger, multi‑center trials.”

Capsulotomy possesses an established clinical legacy. Longer‑standing variations have addressed severe psychiatric indications for decades, with SRS capsulotomy specifically examined predominantly for treatment‑resistant obsessive‑compulsive disorder.

“With its capacity to access a highly localized neural substrate without craniotomy or electrode placement, SRS enables interruption of maladaptive circuits while sparing adjacent brain architecture,” he explained. “The objective is to diminish pathological activity linked to severe, enduring symptoms while minimizing unintended neurocognitive impacts.”

Earlier feasibility data involving three similarly challenging cases demonstrated meaningful alleviation of suicidal thoughts and absence of cognitive or neurological sequelae, providing foundation for the current investigation of twenty patients with chronic, treatment‑resistant depression, half of whom presented with comor­die obsessive‑compulsive disorder.

The group averaged 60 years old, with symptom onset averaging thirty‑three years. Seven patients had proven resistance to transcranial magnetic stimulation, twelve to electroconvulsive therapy, and eight to ketamine.

The eighteen eligible participants began the trial with an average baseline Beck Depression Inventory (BDI) score of 32.4 on a 0‑to‑63 scale, improving to 15.5 among the thirteen subjects monitored for more than twelve months post‑treatment. Depressant symptom relief manifested rapidly, with the mean BDI declining to 18.2 after three months. For the ten non‑OCD cases, the trajectory moved from an initial 34.6 to 15.8 at ultimate assessment. Overall, the mean BDI stood at 17.3 at the end of the study, peaking at thirty‑five months.

Among the ten patients with co‑morbid OCD, Y‑BOCS scores shifted substantially: a mean of 30.0 prior to radiation rose to 17.7 within three months. Two subsequent quarterly‑long followers achieved additional drops to 8 and 16 respectively, maintaining an average of 18.8 for those followed beyond twelve months.

Cognitive status was evaluated using the Montreal Cognitive Assessment (MoCA); baseline averages of 26.3 ranged from 27 to 29 at twelve‑month intervals and beyond.

Khattab clarified that the trial was administered solely at Vanderbilt University Medical Center in Nashville, Tennessee, during his tenure there.

Source link